PeptiQuant™ Onco Kits
Paired Wild-Type and Mutant peptide assays
Quantitative Protein Assays for Cancer Mutations
Ready assays of the 1,000 most prevalent recurrent cancer variants
PeptiQuantTM Onco is a targeted proteogenomics kit designed to translate recurrent cancer mutations into deployable, quantitative protein assays. Starting from curated cancer variant catalogues, Onco predicts and prioritizes analytically tractable variant-containing peptides and provides paired assays for the corresponding wild-type and mutant peptide forms. Using unlabeled and stable isotope-labeled synthetic standards together with empirically optimized acquisition parameters, the kit supports robust targeted measurements and enablesabsolute quantification of both peptide forms. By directly measuring mutation-associated protein expression, Onco enables determination of protein-level mutation rates and provides a scalable route from cancer variant catalogues to actionable protein-level assays.
Fig. 1 and 2: KRAS protein with the peptide region containing the G12V mutation highlighted. Green and red show WT and mutant peptides, which are paired as unlabeled and stable isotope-labeled standards. 
Applications
Onco targets ~ 1,000 clinically relevant cancer mutations representing major oncogenic drivers and therapeutic targets. Commercialized by MRM Proteomics and Agilent Technologies, the platform provides standardized mass spectrometry kits, educational support, and customized services through Onco database to enable scalable implementation in both research and clinical settings. By enabling direct measurement of mutation-associated proteins, PeptiQuant™ Onco Kits has the potential to improve treatment stratification, reduce ineffective therapies, lower healthcare costs, and ultimately improve patient outcomes in precision oncology.
Browse the PeptiQuant Onco database
Features
Paired wild-type and mutant peptide assays for recurrent cancer mutations
Computationally driven assay design using prediction and filtering of variant-containing tryptic peptides for uniqueness and analytical suitability.
Ready assays of the 1,000 most prevalent recurrent cancer variants with paired wild-type/mutant peptide assays.
1.7 million candidate variant peptides available for future assay development & panel expansion.
Unlabeled & stable isotope-labeled standards for robust targeted measurement of both peptide forms.
Empirically optimized acquisition parameters and transitions.
Absolute quantification of paired peptide forms for determination of protein-level mutation rates.
Validated in cancer cell lines using deep 4D proteomics and targeted proteomics